TY - JOUR
T1 - Italian Expert Panel on the management of patients with coexisting spondyloarthritis and inflammatory bowel disease
AU - Armuzzi, Alessandro
AU - Olivieri, Ignazio
AU - Cantini, Fabrizio
AU - Castiglione, Fabiana
AU - Gionchetti, Paolo
AU - Orlando, Ambrogio
AU - Salvarani, Carlo
AU - Scarpa, Raffaele
AU - Vecchi, Maurizio
PY - 2014
Y1 - 2014
N2 - Spondyloarthritis (SpA) is a group of diseases with similar clinical, radiologic and serologic features, including SpA associated with inflammatory bowel disease (IBD-associated SpA). Several studies have estimated the occurrence of SpA in IBD patients as ranging from 17% to 39%, confirming that SpA is the most frequent extra-intestinal manifestation in patients with IBD. In this paper, the expert panel presents some red flags to guide clinicians - both rheumatologists and gastroenterologists - to make a correct diagnosis of IBD-associated SpA in clinical practice. IBD-associated SpA classification, clinical presentation and diagnostic work-up are also presented. From the therapeutic point of view, only separate recommendations/guidelines are currently available for the treatment of Crohn's disease, ulcerative colitis and for both axial and peripheral SpA. However, when IBD and SpA coexist, the therapeutic strategy should be modulated to take into account the variable manifestations of IBD in terms of intestinal and extra-intestinal features, and the clinical manifestations of SpA, with particular attention to peripheral enthesitis, dactylitis and anterior uveitis. To our knowledge, this is the first attempt to define therapeutic algorithms for the integrated management of different IBD-associated SpA clinical scenarios.
AB - Spondyloarthritis (SpA) is a group of diseases with similar clinical, radiologic and serologic features, including SpA associated with inflammatory bowel disease (IBD-associated SpA). Several studies have estimated the occurrence of SpA in IBD patients as ranging from 17% to 39%, confirming that SpA is the most frequent extra-intestinal manifestation in patients with IBD. In this paper, the expert panel presents some red flags to guide clinicians - both rheumatologists and gastroenterologists - to make a correct diagnosis of IBD-associated SpA in clinical practice. IBD-associated SpA classification, clinical presentation and diagnostic work-up are also presented. From the therapeutic point of view, only separate recommendations/guidelines are currently available for the treatment of Crohn's disease, ulcerative colitis and for both axial and peripheral SpA. However, when IBD and SpA coexist, the therapeutic strategy should be modulated to take into account the variable manifestations of IBD in terms of intestinal and extra-intestinal features, and the clinical manifestations of SpA, with particular attention to peripheral enthesitis, dactylitis and anterior uveitis. To our knowledge, this is the first attempt to define therapeutic algorithms for the integrated management of different IBD-associated SpA clinical scenarios.
KW - Algorithms
KW - Crohn's disease
KW - Humans
KW - Inflammatory Bowel Diseases
KW - Inflammatory bowel disease
KW - Integrated management
KW - Joints
KW - Remission Induction
KW - Spondylarthritis
KW - Spondyloarthritis
KW - Therapeutic algorithm
KW - Ulcerative colitis
KW - Algorithms
KW - Crohn's disease
KW - Humans
KW - Inflammatory Bowel Diseases
KW - Inflammatory bowel disease
KW - Integrated management
KW - Joints
KW - Remission Induction
KW - Spondylarthritis
KW - Spondyloarthritis
KW - Therapeutic algorithm
KW - Ulcerative colitis
UR - http://hdl.handle.net/10807/64542
U2 - 10.1016/j.autrev.2014.04.003
DO - 10.1016/j.autrev.2014.04.003
M3 - Article
VL - 13
SP - 822
EP - 830
JO - AUTOIMMUNITY REVIEWS
JF - AUTOIMMUNITY REVIEWS
SN - 1873-0183
ER -